{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:54:51Z","timestamp":1789469691574,"version":"build-2803163510"},"reference-count":17,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100020884","name":"Agencia Nacional de Investigaci\u00f3n y Desarrollo","doi-asserted-by":"publisher","award":["1211225"],"award-info":[{"award-number":["1211225"]}],"id":[{"id":"10.13039\/501100020884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2024,8,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title\/>\n            <jats:p>\n              Interferon-gamma (IFN-\u03b3) release assays play a pivotal role in tuberculosis infection (TBI) diagnosis, with QuantiFERON-TB Gold Plus\u2014an enzyme-linked immunosorbent assay (ELISA)\u2014among the most widely utilized. Newer QuantiFERON-TB platforms with shorter turnaround times were recently released. We aimed to evaluate these platforms\u2019 agreement in the diagnosis of TBI. Blood samples from a prospective cohort of tuberculosis household contacts were collected at baseline and after 12 weeks of follow-up, and tested with LIAISON, an automated chemiluminescence immunoassay (CLIA) system, QIAreach, a lateral flow (QFT-LF) semi-automated immunoassay, and the ELISA QuantiFERON-TB Gold Plus platform. Test concordances were analyzed. ELISA vs CLIA overall agreement was 83.3% for all tested samples (120\/144) [Cohen\u2019s kappa coefficient (\u03ba): 0.66 (95% CI: 0.54\u20130.77)]. Samples positive with CLIA provided consistently higher IFN-\u03b3 levels than with ELISA (\n              <jats:italic>P<\/jats:italic>\n              &lt; 0.001). Twenty-four (16.7%) discordant pairs were obtained, all CLIA-positive\/ELISA-negative: 15 (62.5%) had CLIA IFN-\u03b3 levels within borderline values (0.35\u20130.99 IU\/mL) and 9 (37.5%) &gt;0.99 IU\/mL. QFT-LF showed only 76.4% (68\/89) overall agreement with ELISA [\u03ba: 0.53 (95% CI: 0.37\u20130.68)] with 21 (23.6%) discordant results obtained, all QFT-LF-positive\/ELISA-negative. Overall concordance between ELISA and CLIA platforms was substantial, and only moderate between ELISA and QFT-LF. The CLIA platform yielded higher IFN-\u03b3 levels than ELISA, leading to an almost 17% higher positivity rate. The techniques do not seem interchangeable, and validation against other gold standards, such as microbiologically-confirmed tuberculosis disease, is required to determine whether these cases represent true new infections or whether CLIA necessitates a higher cutoff.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>IMPORTANCE<\/jats:title>\n            <jats:p>\n              Tuberculosis is an airborne infectious disease caused by\n              <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n              that affects over 10 million people annually, with over 2 billion people carrying an asymptomatic tuberculosis infection (TBI) worldwide. Currently, TBI diagnosis includes tuberculin skin test and the blood-based interferon-gamma (IFN-\u03b3) release assays, with Qiagen QuantiFERON-TB Gold Plus (QFT) being among those most widely utilized. We evaluated Qiagen's newer QFT platforms commercially available in a prospective cohort of tuberculosis contacts. A substantial agreement was obtained between the current QFT-enzyme-linked immunosorbent assay (ELISA) and the new QFT-chemiluminescence immunoassay (CLIA) platform, although QFT-CLIA provided higher concentrations of IFN-\u03b3, leading to a 16.6% higher positivity rate. We highlight that both platforms may not be directly interchangeable and that further validation is required.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1128\/spectrum.00469-24","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T13:00:31Z","timestamp":1720443631000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":11,"title":["Evaluation of concordance of new QuantiFERON-TB Gold Plus platforms for\n            <i>Mycobacterium tuberculosis<\/i>\n            infection diagnosis in a prospective cohort of household contacts"],"prefix":"10.1128","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4712-3302","authenticated-orcid":true,"given":"Cinthya","family":"Ruiz-Tagle","sequence":"first","affiliation":[{"name":"Departamento de Enfermedades Infecciosas del Adulto, Escuela de Medicina, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Departamento de Laboratorios Cl\u00ednicos, Escuela de Medicina, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6386-9369","authenticated-orcid":true,"given":"Mariluz","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Equipo T\u00e9cnico de Tuberculosis, Direcci\u00f3n de Servicio de Salud Oriente, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7223-9665","authenticated-orcid":true,"given":"Mar\u00eda Elvira","family":"Balcells","sequence":"additional","affiliation":[{"name":"Departamento de Enfermedades Infecciosas del Adulto, Escuela de Medicina, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"},{"name":"Red de Salud UC-CHRISTUS, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/apm.13025"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00159-20"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01436-20"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jalm\/jfab012"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00603-21"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00295-23"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00780-20"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.21.0391"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pulmoe.2021.07.003"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00511-2021"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02563-2021"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0279882"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.4067\/s0034-98872020000200151"},{"key":"e_1_3_4_18_2","unstructured":"QuantiFERON-TB Gold Plus (QFT-Plus) ELISA package insert. 1083163 Rev. 2019"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-016-2888-7"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01370-21"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.2307\/2529310"}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.00469-24","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.00469-24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T13:14:36Z","timestamp":1722950076000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.00469-24"}},"subtitle":[],"editor":[{"given":"Bobby G.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,8,6]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,6]]}},"alternative-id":["10.1128\/spectrum.00469-24"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.00469-24","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,6]]},"assertion":[{"value":"2024-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00469-24"}}